Invesaro

Stocks REGN Earnings

Earnings

Regeneron Pharmaceuticals, Inc. (REGN) earnings

Quarterly results of Regeneron Pharmaceuticals, Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 8 quarters, the latest results release and when the next one is expected.

Free, no password. An email when REGN files with the SEC.

Next earnings date

Regeneron Pharmaceuticals, Inc. is expected to report around January 11, 2027. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.

Latest quarter: Q3 FY2026

In Q3 FY2026 (ended September 30, 2026) Regeneron Pharmaceuticals, Inc. reported revenue of $5.1B (+36.3% on the same quarter a year earlier) and net income of $1.9B (+33.5% on the same quarter a year earlier).

Diluted earnings per share were $18.45 (+35.5% on the same quarter a year earlier).

Filed with the SEC on October 30, 2026.

The latest results release

Regeneron amended its collaboration with Sanofi to co-develop four new antibodies, securing an upfront payment and resolving litigation.

Sanofi will make an upfront payment to Regeneron of $1.0 billion to co-develop four new antibodies.

October 6, 2026 · Read the release explained

Revenue by quarter
Q4 24: $3.8B $3.8B Q4 24Q1 25: $3B $3B Q1 25Q2 25: $3.7B $3.7B Q2 25Q3 25: $3.8B $3.8B Q3 25Q4 25: $3.9B $3.9B Q4 25Q1 26: $3.6B $3.6B Q1 26Q2 26: $4.3B $4.3B Q2 26Q3 26: $5.1B $5.1B Q3 26
Net income by quarter
Q4 24: $917.7M $917.7M Q4 24Q1 25: $808.7M $808.7M Q1 25Q2 25: $1.4B $1.4B Q2 25Q3 25: $1.5B $1.5B Q3 25Q4 25: $844.6M $844.6M Q4 25Q1 26: $727.2M $727.2M Q1 26Q2 26: $1.3B $1.3B Q2 26Q3 26: $1.9B $1.9B Q3 26

Quarter by quarter

QuarterEndedRevenuevs year agoNet incomeEPS
Q3 FY2026September 30, 2026$5.1B+36.3%$1.9B$18.45
Q2 FY2026June 30, 2026$4.3B+16.7%$1.3B$12.23
Q1 FY2026March 31, 2026$3.6B+19%$727.2M$6.75
Q4 FY2025December 31, 2025$3.9B+2.5%$844.6M-
Q3 FY2025September 30, 2025$3.8B-$1.5B$13.62
Q2 FY2025June 30, 2025$3.7B-$1.4B$12.81
Q1 FY2025March 31, 2025$3B-$808.7M$7.27
Q4 FY2024December 31, 2024$3.8B-$917.7M-

Fourth quarters are the fiscal year minus the first three, as most companies report no separate Q4 figures.

Results filings

When is Regeneron Pharmaceuticals, Inc.'s next earnings date?

Regeneron Pharmaceuticals, Inc. is expected to report around January 11, 2027. That is an estimate from its filing rhythm (a year after the same report last year), not a date the company has announced.

What were Regeneron Pharmaceuticals, Inc.'s latest quarterly results?

For Q3 FY2026, which ended September 30, 2026, Regeneron Pharmaceuticals, Inc. reported revenue of $5.1B and net income of $1.9B (+33.5% on the same quarter a year earlier). The figures come from its filing with the SEC.

Is Regeneron Pharmaceuticals, Inc.'s revenue growing?

Revenue in Q3 FY2026 was $5.1B, up 36.3% from $3.8B in the same quarter a year earlier.

Get an email when REGN reports

Follow REGN and we email you its next results the day they are filed, with the numbers explained.

Free, no password. An email when REGN files with the SEC.

Source: quarterly figures Regeneron Pharmaceuticals, Inc. tags in its 10-Q and 10-K filings (SEC EDGAR XBRL). Not investment advice.

Everything about Regeneron Pharmaceuticals, Inc.